Vanguard Group
PDLI

Vanguard Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Vanguard Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,914,315
Closed -$18.6M – 4272
2020
Q3 		$18.6M Sell
5,914,315
-53,222
-0.9% -$170K ﹤0.01% 2493
2020
Q2 		$17.4M Buy
5,967,537
+339,548
+6% +$1.07M ﹤0.01% 2489
2020
Q1 		$15.9M Buy
5,627,989
+104,037
+2% +$335K ﹤0.01% 2394
2019
Q4 		$17.9M Sell
5,523,952
-717,192
-11% -$2.08M ﹤0.01% 2582
2019
Q3 		$13.5M Sell
6,241,144
-3,085,747
-33% -$8.25M ﹤0.01% 2670
2019
Q2 		$29.3M Sell
9,326,891
-1,304,470
-12% -$4.23M ﹤0.01% 2348
2019
Q1 		$39.5M Buy
10,631,361
+551,973
+5% +$1.86M ﹤0.01% 2203
2018
Q4 		$29.2M Sell
10,079,388
-388,137
-4% -$1.07M ﹤0.01% 2274
2018
Q3 		$27.5M Sell
10,467,525
-2,711,435
-21% -$6.65M ﹤0.01% 2430
2018
Q2 		$30.8M Buy
13,178,960
+648,092
+5% +$1.81M ﹤0.01% 2368
2018
Q1 		$36.8M Sell
12,530,868
-424,333
-3% -$1.16M ﹤0.01% 2223
2017
Q4 		$35.5M Buy
12,955,201
+491,368
+4% +$1.51M ﹤0.01% 2234
2017
Q3 		$42.3M Sell
12,463,833
-406,628
-3% -$1.13M ﹤0.01% 2120
2017
Q2 		$31.8M Sell
12,870,461
-1,309,657
-9% -$3.01M ﹤0.01% 2250
2017
Q1 		$32.2M Buy
14,180,118
+827,830
+6% +$1.83M ﹤0.01% 2204
2016
Q4 		$28.3M Sell
13,352,288
-164,442
-1% -$459K ﹤0.01% 2251
2016
Q3 		$45.3M Buy
13,516,730
+2,117,287
+19% +$6.72M ﹤0.01% 1975
2016
Q2 		$35.8M Buy
11,399,443
+561,405
+5% +$1.87M ﹤0.01% 2045
2016
Q1 		$36.1M Sell
10,838,038
-360,230
-3% -$1.12M ﹤0.01% 2019
2015
Q4 		$39.6M Buy
11,198,268
+82,012
+0.7% +$343K ﹤0.01% 1993
2015
Q3 		$55.9M Sell
11,116,256
-115,982
-1% -$665K ﹤0.01% 1801
2015
Q2 		$72.2M Sell
11,232,238
-289,136
-3% -$1.94M ﹤0.01% 1742
2015
Q1 		$81.1M Buy
11,521,374
+266,961
+2% +$1.93M 0.01% 1649
2014
Q4 		$86.8M Buy
11,254,413
+923,687
+9% +$7.31M 0.01% 1513
2014
Q3 		$77.2M Buy
10,330,726
+161,020
+2% +$1.49M 0.01% 1539
2014
Q2 		$98.4M Buy
10,169,706
+212,229
+2% +$1.89M 0.01% 1409
2014
Q1 		$82.7M Buy
9,957,477
+1,219,176
+14% +$10.4M 0.01% 1473
2013
Q4 		$73.8M Buy
8,738,301
+85,315
+1% +$719K 0.01% 1524
2013
Q3 		$69M Buy
8,652,986
+583,352
+7% +$4.69M 0.01% 1503
2013
Q2 		$62.3M Buy
+8,069,634
New +$62.9M 0.01% 1478

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Vanguard Group's PDLI Position: Q4 2020 in Review

Vanguard Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 5,914,315 shares — an estimated $18.6M sold.

Vanguard Group first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $98.4M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Vanguard Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Vanguard Group sold 5,914,315 PDL BioPharma, Inc. shares in Q4 2020, an estimated $18.6M.
  • Vanguard Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Vanguard Group's PDL BioPharma, Inc. position peaked at $98.4M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Vanguard Group's 13F filing for Q4 2020, filed 12 Feb 2021.